B00 Stock Overview
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Biocept, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.80 |
| 52 Week High | US$34.73 |
| 52 Week Low | US$6.06 |
| Beta | 0.82 |
| 1 Month Change | 0% |
| 3 Month Change | 12.21% |
| 1 Year Change | -80.42% |
| 3 Year Change | -96.73% |
| 5 Year Change | -99.13% |
| Change since IPO | -99.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| B00 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | 1.8% |
| 1Y | -80.4% | -22.4% | 2.2% |
Return vs Industry: B00 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: B00 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| B00 volatility | |
|---|---|
| B00 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B00 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine B00's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 50 | Antonino Morales | biocept.com |
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer.
Biocept, Inc. Fundamentals Summary
| B00 fundamental statistics | |
|---|---|
| Market cap | €1.48m |
| Earnings (TTM) | -€33.87m |
| Revenue (TTM) | €6.03m |
0.2x
P/S Ratio0.0x
P/E RatioIs B00 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B00 income statement (TTM) | |
|---|---|
| Revenue | US$6.59m |
| Cost of Revenue | US$21.13m |
| Gross Profit | -US$14.55m |
| Other Expenses | US$22.47m |
| Earnings | -US$37.02m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -25.20 |
| Gross Margin | -220.89% |
| Net Profit Margin | -562.12% |
| Debt/Equity Ratio | 0% |
How did B00 perform over the long term?
See historical performance and comparison